Indexed on: 20 Dec '18Published on: 20 Dec '18Published in: Diabetes, Obesity and Metabolism
To describe global patterns of insulin treatment and to assess impact of patient, provider, health system, and economic influences on treatment decisions for patients with insulin-treated type 2 diabetes (T2D). This prospective cohort study of insulin-treated patients with T2D was conducted across 18 countries categorized as high, upper-middle, or lower-middle income regions. Information collected from patients included diabetes knowledge, experiences, and interactions with their healthcare provider. Physician information collected included specialty, practice size, availability of diabetes support services, volume of diabetes patients treated, and time spent per patient. Physicians determined an individualized hemoglobin A1c (HbA1c) target for each patient by the start of the study. Changes in T2D therapies and HbA1c were recorded for two years. Complete treatment data were available on 2528 patients. Median age was 61 years and median duration of diabetes was 11.4 years. Changes to treatment regimen occurred in 90.0% of patients, but were less common in higher economic status countries (p<0.001). Most treatment changes were to insulin, with dose changes the most common type of change. Overall predictors of change in insulin therapy included younger age, use of any insulin regimen other than basal only, higher mean baseline HbA1c, and longer duration of T2D. HbA1c levels remained constant regardless of regional economic status. At baseline, 20.6% of patients were at their HbA1c target; at two years this was 26.8%. Among insulin-treated patients with T2D, treatment changes were common; however only approximately one-fourth of individuals achieved their HbA1c target. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.